Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|April 29, 2008
Premier and Octagon Announce Strategic Partnership
A new partnership between Premier Research Group and Octagon Research Solutions will expand the companies' solution sets.
Advertisement
Philadelphia, PA-April 29, 2008-Premier Research Group (
This new partnership combines Octagon’s expertise in electronic submissions with Premier Research’s extensive clinical expertise across a wide array of therapeutic areas. The partnership enables Premier Research to offer Octagon’s electronic submission capabilities as part of its Regulatory Affairs services and for Octagon to offer Premier’s regulatory development and scientific strategy.
James Ottinger, vice president of global consulting and compliance for Premier Research noted, “Our partnership with Octagon broadens our services by offering Octagon’s proven expertise in the technical aspects of electronic submissions while we continue to focus on our core strengths of regulatory strategy and consulting. We are pleased to be working with an organization that also values our deep commitment to being a ‘solution provider’ for our clients.”
“Premier Research has a solid history of consistent, quality delivery that aligns with our own high standard of operation. We believe that the collaboration will ultimately provide a strong product for our valued customers,” commented Jim Walker, chairman and chief excutive officer, Octagon Research Solutions.
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
3
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
4
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
5